Terms ending in 2037
Bayer Pharma Aktiengesellschaft
Every in-force patent on Bayer Pharma Aktiengesellschaft's record whose computed term ends in 2037, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,435,396 | New 2-Substituted Indazoles, Methods for Producing Same, Pharmaceutical Preparations That Contain Same, and Use of Same to Produce Drugs In force · High confidence | Bayer Pharma Aktiengesellschaft | In force | High confidence | |
| US 10,966,986 | Compounds, Compositions and Methods for Cancer Patient Stratification and Cancer Treatment In force · High confidence | Bayer Pharma Aktiengesellschaft | In force | High confidence | |
| US 11,787,797 | 4,5-Annulated 1,2,4-Triazolones In force · Medium confidence | Bayer Aktiengesellschaft and Bayer Pharma Aktiengesellschaft | In force | Medium confidence | |
| US 12,144,865 | Antibody Drug Conjugates with Enzymatically Cleavable Groups In force · Medium confidence | Bayer Pharma Aktiengesellschaft | In force | Medium confidence | |
| US 10,501,417 | Synthesis of Indazoles In force · High confidence | Bayer Pharma Aktiengesellschaft | In force | High confidence | |
| US 10,501,437 | Crystalline Forms of N-[2-(3-Hydroxy-3-Methylbutyl)-6-(2-Hydroxypropan-2-YL)-2H-INDAZOL-5-YL]-6-(TRIFLUOROMETHYL)PYRIDINE-2-Carboxamide In force · High confidence | Bayer Pharma Aktiengesellschaft | In force | High confidence | |
| US 10,633,365 | Synthesis of Indazoles In force · High confidence | Bayer Pharma Aktiengesellschaft | In force | High confidence | |
| US 10,759,758 | Polymorphic Form of N-{6-(2-Hydroxypropan-2-YL)-2-[2-(METHYLSULPHONYL)ETHYL]-2H-INDAZOL-5-YL}-6-(TRIFLUOROMETHYL)PYRIDINE-2-Carboxamide In force · High confidence | Bayer Pharma Aktiengesellschaft | In force | High confidence | |
| US 10,844,016 | Aromatic Sulfonamide Derivatives In force · High confidence | Bayer Pharma Aktiengesellschaft | In force | High confidence | |
| US 10,722,501 | Substituted 5,6,7,8-Tetrahydro[1,2,4]triazolo[4,3-a]pyridine-3(2h)-ones and 2,5,6,7-Tetrahydro-3H-pyrrolo[2,1-c][1,2,4]triazol-3-ones, and Use Thereof In force · High confidence | Bayer Pharma Aktiengesellschaft | In force | High confidence | |
| 23 more term ends in 2037 · Pro | |||||
10 of 33 patents shown. Soonest term end first, then patent number.
Pro members see all 33.
30 of these are in force and held by Bayer Pharma Aktiengesellschaft.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.